New hope for kids with rare swelling disorder: early access drug available

NCT ID NCT07216378

AVAILABLE Disease control Sponsor: KalVista Pharmaceuticals, Ltd. Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 29 times

Summary

This program provides early access to an investigational drug called sebetralstat for children aged 2 to 11 with hereditary angioedema (HAE). HAE causes sudden, painful swelling attacks. The drug is taken at the time of an attack to help control symptoms. The program is for children who have already been in a sebetralstat study or are new to the drug, and whose doctor believes they may benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

KalVista Investigative Site
AVAILABLE

Evansville, Indiana, 47715, United States
KalVista Investigative Site
AVAILABLE

Wheaton, Maryland, 20902, United States
KalVista Investigative Site
AVAILABLE

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

HEREDITARY ANGIOEDEMA